Clinical Education

This series of educational slide decks gives a comprehensive overview of the role of IL-17A in psoriasis. Across the following modules, IL-17A in pathophysiology is explained, disease manifestation and assessment tools are described and treatment guidelines and patient goals are outlined. Clinical trial data for the IL-17A inhibitor secukimumab is also presented. Click on the image and/or hyperlink to view the slides.

IL-17 in the Pathophysiology of Psoriasis

Secukinumab Clinical Trial Data: Efficacy

  Number of slides: 26

This presentation describes 4 core double-blind, placebo-controlled phase 3 trials with Secukinumab in psoriasis alongside an additional double-blind, comparator-controlled head-to-head trial, with particular focus on data from the ERASURE, FIXTURE and CLEAR efficacy studies.

IL-17 in the Pathophysiology of Psoriasis

  Number of slides: 23

These slides demonstrate the key role of the cytokine IL-17A in psoriasis immunopathogenesis and how IL-17A inhibition leads to downregulation of expression of proteins associated with psoriatic lesion formation.

Psoriasis and Psoriasis Disease Assessment Tools

  Number of slides: 27

A host of psoriasis disease assessment tools have been devised to correlate patient and dermatologist views on each individual case of psoriasis, in order to classify the disease and aid treatment decisions.

Psoriasis Treatment Goals and Treatment Overview

  Number of slides: 29

Treatment guidelines are outlined in this presentation and the treatment goals sought to lead to best patient outcomes and improved quality of life.